Generex Biotechnology Corporation (OTCMKTS:GNBT) has been rather consistent with only slight variations over last 52 weeks. GNBT is currently trading at $0.02.
Lowest the company saw in the last 52 weeks was $0.01 and the highest at $0.06.
Generex Biotechnology Corporation (OTCMKTS:GNBT) has been keeping itself in news and was also able to catch attention of stock Promoters. On December 17, 2014 GNBT announced its participation in a MedCannAccess partnership with CannScience Innovations Inc.
Generex Biotechnology Corporation (OTCMKTS:GNBT) is engaged primarily in the research and development of drug delivery systems and technologies. The Company’s primary focus is on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly owned subsidiary, Antigen, it has expanded its focus to include immunomedicines incorporating vaccine formulations. The Company has identified several molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones, but has focused its development efforts primarily on one pharmaceutical product, Generex Oral-lyn an insulin formulation administered as a fine spray into the oral cavity using its hand-held aerosol spray applicator known as RapidMist.
Generex Biotechnology Corporation (OTCMKTS:GNBT) announced its participation in a MedCannAccess (www.MedCannAccess.com) partnership with CannScience Innovations Inc.
MedCannAccess today announced that it has acquired a substantial minority equity stake in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.
“Successful companies in the cannabis industry will have three legs to their platform: quality production, an effective patient acquisition and retention strategy, and innovative research and development capabilities,” said Rade Kovacevic, VP Business Development at MedCannAccess. “We believe we have strong positions already in the first two legs, and through this investment, we have solidified the R&D piece of our platform, positioning us as a leader in future cannabinoid drug development. Physicians and patients alike have been calling for access to cannabinoid products that do not require smoking or inhalation; this partnership will allow us to take that significant step forward.”
CannScience is an R&D biopharmaceutical company established in Toronto, Canada to conduct research and product development for extracts and formulations related to medical cannabis and its derivatives. CannScience is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of cannabinoids and potentially how they integrate with various medical devices and drug delivery technologies. CannScience intends to develop commercial ready products and obtain regulatory approval for RapidMist™ in the Canadian and international jurisdictions. The company’s founders have a wealth of experience in the life sciences industry and access to laboratories at some of the top research institutions in Canada .
“CannScience is working to develop its product pipeline which will include proprietary drug, device, and delivery technologies,” said Har Grover , the CEO of CannScience. On November 18, 2014 , CannScience entered into a non-binding Letter of Intent with Generex to license Generex’s proprietary RapidMist™ drug delivery technologies to CannScience for the buccal delivery of cannabis derived products into the bloodstream.
MedCannAccess was established to provide access to the highest-quality of medical cannabis products developed through research and innovation, aiming to improve the quality of life for persons with a wide range of conditions including chronic disabilities and terminal illnesses. MedCannAccess is a proud member of the Canadian Medical Cannabis Industry Association, Toronto Board of Trade, Guelph Chamber of Commerce and Ontario Chamber of Commerce.
Generex Biotechnology Corporation (OTCMKTS:GNBT) wasn’t able to generate revenue for the period ending July 31, 2014
It has total assets of $5.52 M and liabilities stand at $11.61 M with shareholder’s equity negatively at $6.09 M.
Keeping in view the fundamentals, market capitalization at $15.49 M is clearly overvalued.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...